-- Scott Roberts
WEDNESDAY, Dec. 18, 2013 (HealthDay News) -- Anoro Ellipta (umeclidinium and vilanterol inhalation powder) has been approved by the U.S. Food and Drug Administration for once-daily treatment of chronic obstructive pulmonary disease (COPD).
COPD, an umbrella term that includes the lung diseases bronchitis and emphysema, is a progressive condition that interferes with breathing. Symptoms may include chest tightness, chronic cough and overproduction of phlegm. It's the third-leading cause of death in the United States, the FDA said in a news release.
Anoro Ellipta, a combination of two approved medications, relaxes the lung airways to help breathing. The drug's safety and effectiveness were evaluated in clinical trials involving more than 2,400 people diagnosed with COPD.
The drug's label includes a warning that users have an increased risk of asthma-related death. However, the medication has not been evaluated in people with asthma, nor should it be taken as a treatment for asthma or for sudden breathing problems, the agency stressed.
Potential serious side effects of the new drug include narrowing of the respiratory airways, cardiovascular problems, glaucoma and worsening urinary retention. The most common side effects include sore throat, sinus infection, respiratory tract infection, constipation, diarrhea, extremity pain and muscle spasms.
Anoro Ellipta is produced by GlaxoSmithKline, based in Research Triangle Park, N.C.
The U.S. National Library of Medicine has more about COPD.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.